Keeping ’Em Honest: The Current Crisis of Confidence in Antidepressants
J Clin Psychiatry 2011;72(7):1015 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
On May 14, 2010, Dr Andrew A. Nierenberg assembled a roundtable conference of experts to address “the current crisis of confidence in antidepressants.” In the Journal commentary that resulted from this conference, Dr Nierenberg comments, “It is difficult for us to understand the popular perception that industry trials are biased….”
The problem may not be so much that data from industry trials may not be validly obtained, but, more insidiously, that they may be “spun” by the authors who frequently report small, albeit statistically significant, differences as if they are clinically relevant when they often are not.